Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM_Ethikrat.jpg450850Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-10 06:46:512019-05-10 06:46:51Ethics Council calls for moratorium of clinical germline manipulation
Immunotherapy and infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc.
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2019_timothydyer.jpg5631000h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-07 13:03:002019-05-07 13:03:00Lessons from a former poster child
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
https://european-biotechnology.com/wp-content/uploads/2024/04/Confo.jpeg18752500Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-07 10:45:382019-05-07 10:45:38Confo Therapeutics raise €30m in Series A financing
LEA, the Lipidomics Excellence Award, was founded to strengthen life sciences through lipidomics. Over the course of April, the LEA jury deliberated on the submitted projects to announce the three LEA awardees.
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
https://european-biotechnology.com/wp-content/uploads/2024/04/ELF-IMI.jpg8001200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-02 14:46:022019-05-02 14:46:02European Lead Factory gets €36.5m support from IMI
Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgène’s armed oncolytic immunotherapies.
https://european-biotechnology.com/wp-content/uploads/2024/04/transgene_headquarters.jpg7491920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-02 08:27:222019-05-02 08:27:22AstraZeneca set to licence 5 programmes from Transgène SA
Ethics Council calls for moratorium of clinical germline manipulation
Latest NewsFollowing the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
BioNtech aquires antibody assets from MabVax Therapeutics
Latest NewsMS linked to epigenetic changes in immune cells
Latest NewsEpigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Whitepaper Spotlight: Proactive Biomarker Planning to Optimize Clinical Trials
Sponsored PublicationsOncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
Lessons from a former poster child
OpinionWith partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
Confo Therapeutics raise €30m in Series A financing
Latest NewsThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
LEA Jury announces the Winners of LEA 2019
Sponsored PublicationsResearchers report how body fat affects imune cells
Latest NewsUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets €36.5m support from IMI
Latest NewsThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Latest News